 RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high bone marrow ablative doses. Total marrow irradiation TMIablative dose radiation therapy is another modality capable of destroying myeloma cells. Autologous peripheral bloodstem cell transplant ASCT given after either melphalan or following TMI aimed at the bone marrow containing areas of the skeleton, the site of origin of myeloma cells will shorten the durationalleviate the severity of both melphalan and marrow irradiation-associated side effects. Lenalidomide, an effective agent on its own right for the treatment of myeloma, has been shown to further enhance the beneficial effects of autologous stem cell transplants when given as maintenance therapy. 